# EDGAR Filing Document

**Accession Number:** 0000084748
**File Stem:** 0000084748-26-000023
**Filing Date:** 2026-4
**Character Count:** 109989
**Document Hash:** b077aa861ac30aa692f890102130227d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000084748-26-000023.hdr.sgml**: 20260429

**ACCESSION NUMBER**: 0000084748-26-000023

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 92

**CONFORMED PERIOD OF REPORT**: 20260331

**FILED AS OF DATE**: 20260429

**DATE AS OF CHANGE**: 20260428

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ROGERS CORP
- **CENTRAL INDEX KEY:** 0000084748
- **STANDARD INDUSTRIAL CLASSIFICATION:** PLASTICS, MATERIALS, SYNTH RESINS & NONVULCAN ELASTOMERS [2821]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 060513860
- **STATE OF INCORPORATION:** MA
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-04347
- **FILM NUMBER:** 26909569

**BUSINESS ADDRESS:**
- **STREET 1:** 2225 W CHANDLER BLVD
- **CITY:** CHANDLER
- **STATE:** AZ
- **ZIP:** 85224
- **BUSINESS PHONE:** 480-917-6000

**MAIL ADDRESS:**
- **STREET 1:** 2225 W CHANDLER BLVD
- **CITY:** CHANDLER
- **STATE:** AZ
- **ZIP:** 85224

?xml version='1.0' encoding='ASCII'? rog-20260331

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**_______________________________**

**FORM 10-Q**

**<u>_______________________________</u>**

☒ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the quarterly period ended March 31, 2026**

**or**

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the transition period from _______________ to _______________**

**Commission file number 1-4347**

**<u>_______________________________</u>**

**ROGERS CORPORATION**

(Exact Name of Registrant as Specified in its Charter)

**<u>_______________________________</u>**

---

| | |
|:---|:---|
| **Massachusetts** | **06-0513860** |
| (State or Other Jurisdiction of | (I. R. S. Employer Identification No.) |
| Incorporation or Organization) | |

---

**2225 W. Chandler Blvd., Chandler, Arizona 85224-6155**

(Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code: **(480) 917-6000**

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | | |
|:---|:---|:---|:---|
| Title of each class | Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| **Capital Stock,** | **par value $1.00 per share** | **ROG** | **New York Stock Exchange** |

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer", "accelerated filer", "smaller reporting company", and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Large accelerated filer | ☒ | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accelerated filer | ☐ |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Non-accelerated filer  | ☐ | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Smaller reporting company  | ☐ |
| | | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Emerging growth company  | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒

The number of shares outstanding of the registrant's capital stock as of April 24, 2026 was 17,848,535.

------

**ROGERS CORPORATION**

**FORM 10-Q**

**March 31, 2026**

---

| | | | |
|:---|:---|:---|:---|
| **TABLE OF CONTENTS** | **TABLE OF CONTENTS** | **TABLE OF CONTENTS** | **TABLE OF CONTENTS** |
| **<u>Part I – Financial Information</u>** | **<u>Part I – Financial Information</u>** | **<u>Part I – Financial Information</u>** | **<u>Part I – Financial Information</u>** |
| | <u>[Item 1.](#ief8df7c3fc2d48d7b25f0b2c6b010907_16)</u> | <u>[Condensed Consolidated Financial Statements (Unaudited):](#ief8df7c3fc2d48d7b25f0b2c6b010907_16)</u> | |
| | | &nbsp;&nbsp;&nbsp;&nbsp;<u>[Condensed Consolidated Statements of Operations](#ief8df7c3fc2d48d7b25f0b2c6b010907_19)</u> | <u>[4](#ief8df7c3fc2d48d7b25f0b2c6b010907_19)</u> |
| | | &nbsp;&nbsp;&nbsp;&nbsp;<u>[Condensed Consolidated Statements of Comprehensive Income (Loss)](#ief8df7c3fc2d48d7b25f0b2c6b010907_22)</u> | <u>[5](#ief8df7c3fc2d48d7b25f0b2c6b010907_22)</u> |
| | | &nbsp;&nbsp;&nbsp;&nbsp;<u>[Condensed Consolidated Statements of Financial Position](#ief8df7c3fc2d48d7b25f0b2c6b010907_25)</u> | <u>[6](#ief8df7c3fc2d48d7b25f0b2c6b010907_25)</u> |
| | | &nbsp;&nbsp;&nbsp;&nbsp;<u>[Condensed Consolidated Statements of Shareholders' Equity](#ief8df7c3fc2d48d7b25f0b2c6b010907_28)</u> | <u>[7](#ief8df7c3fc2d48d7b25f0b2c6b010907_28)</u> |
| | | &nbsp;&nbsp;&nbsp;&nbsp;<u>[Condensed Consolidated Statements of Cash Flows](#ief8df7c3fc2d48d7b25f0b2c6b010907_31)</u> | <u>[8](#ief8df7c3fc2d48d7b25f0b2c6b010907_31)</u> |
| | | &nbsp;&nbsp;&nbsp;&nbsp;<u>[Notes to Condensed Consolidated Financial Statements](#ief8df7c3fc2d48d7b25f0b2c6b010907_34)</u> | <u>[9](#ief8df7c3fc2d48d7b25f0b2c6b010907_34)</u> |
| | <u>[Item 2.](#ief8df7c3fc2d48d7b25f0b2c6b010907_88)</u> | <u>[Management's Discussion and Analysis of Results of Operations and Financial Position](#ief8df7c3fc2d48d7b25f0b2c6b010907_88)</u> | <u>[23](#ief8df7c3fc2d48d7b25f0b2c6b010907_88)</u> |
| | <u>[Item 3.](#ief8df7c3fc2d48d7b25f0b2c6b010907_115)</u> | <u>[Quantitative and Qualitative Disclosures About Market Risk](#ief8df7c3fc2d48d7b25f0b2c6b010907_115)</u> | <u>[28](#ief8df7c3fc2d48d7b25f0b2c6b010907_115)</u> |
| | <u>[Item 4.](#ief8df7c3fc2d48d7b25f0b2c6b010907_118)</u> | <u>[Controls and Procedures](#ief8df7c3fc2d48d7b25f0b2c6b010907_118)</u> | <u>[28](#ief8df7c3fc2d48d7b25f0b2c6b010907_118)</u> |
| **<u>Part II – Other Information</u>** | **<u>Part II – Other Information</u>** | **<u>Part II – Other Information</u>** | **<u>Part II – Other Information</u>** |
| | <u>[Item 1.](#ief8df7c3fc2d48d7b25f0b2c6b010907_124)</u> | <u>[Legal Proceedings](#ief8df7c3fc2d48d7b25f0b2c6b010907_124)</u> | <u>[29](#ief8df7c3fc2d48d7b25f0b2c6b010907_124)</u> |
| | <u>[Item 1A.](#ief8df7c3fc2d48d7b25f0b2c6b010907_127)</u> | <u>[Risk Factors](#ief8df7c3fc2d48d7b25f0b2c6b010907_127)</u> | <u>[29](#ief8df7c3fc2d48d7b25f0b2c6b010907_127)</u> |
| | <u>[Item 5.](#ief8df7c3fc2d48d7b25f0b2c6b010907_133)</u> | <u>[Other Information](#ief8df7c3fc2d48d7b25f0b2c6b010907_133)</u> | <u>[29](#ief8df7c3fc2d48d7b25f0b2c6b010907_133)</u> |
| | <u>[Item 6.](#ief8df7c3fc2d48d7b25f0b2c6b010907_136)</u> | <u>[Exhibits](#ief8df7c3fc2d48d7b25f0b2c6b010907_136)</u> | <u>[29](#ief8df7c3fc2d48d7b25f0b2c6b010907_136)</u> |
| | | <u>[Signatures](#ief8df7c3fc2d48d7b25f0b2c6b010907_139)</u> | <u>[30](#ief8df7c3fc2d48d7b25f0b2c6b010907_139)</u> |

---

**Forward-Looking Statements**

This Quarterly Report on Form 10-Q (this "Form 10-Q") contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Refer to "Forward-Looking Statements" in Item 2, Management's Discussion and Analysis of Results of Operations and Financial Position for additional information.

------

**ROGERS CORPORATION**

**Defined Terms**<sup>(1)</sup>

---

| | |
|:---|:---|
| **Term** | **Definition** |
| ADAS | Advanced driver assistance systems |
| AES | Advanced Electronics Solutions |
| APAC | Asia - Pacific |
| ASC | Accounting Standards Codification |
| ASU | Accounting Standards Update |
| CODM | Chief Operating Decision Maker |
| EMEA | Europe, the Middle East and Africa |
| EMS | Elastomeric Material Solutions |
| ERP | Enterprise resource planning |
| EV/HEV | Electric Vehicles/Hybrid Electric Vehicles |
| Exchange Act | Securities Exchange Act of 1934, as amended |
| FASB | Financial Accounting Standards Board |
| Fifth Amended Credit Agreement | Fifth Amended and Restated Credit Agreement, dated as of March 24, 2023, among Rogers Corporation, the lenders from time to time party hereto, JPMorgan Chase Bank, N.A., as Administrative Agent and HSBC Bank USA, National Association, Wells Fargo Bank, National Association, Citibank, N.A. and Citizens Bank, N.A., as Co-Syndication Agents |
| Guarantors | Existing and future material domestic subsidiaries |
| INOAC | INOAC Corporation |
| OECD | Organization for Economic Co-operation and Development |
| R&D | Research and development |
| SEC | U.S. Securities and Exchange Commission |
| SG&A | Selling, general and administrative |
| Union Plan | Rogers Corporation Employees' Pension Plan |
| U.S. | United States of America |
| U.S. GAAP | Accounting principles generally accepted in the United States |

---

&nbsp;&nbsp;&nbsp;&nbsp;

 <sup>(1)</sup>Certain terms used within this Form 10-Q are defined in the table above.

------

**Part I – Financial Information**

**Item 1.&nbsp;&nbsp;&nbsp;&nbsp;Financial Statements**

**ROGERS CORPORATION**

**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**

*(Unaudited)*

*(Dollars and shares in millions, except per share amounts)*

---

| | | |
|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** |
| | **March 31, 2026** | March 31, 2025 |
| **Net sales** | $**200.5** | $190.5 |
| Cost of sales | **135.9** | 133.5 |
| **Gross margin** | **64.6** | 57.0 |
| Selling, general and administrative expenses | **41.2** | 44.5 |
| Research and development expenses | **6.7** | 7.1 |
| Restructuring and impairment charges | **5.9** | 5.9 |
| Other operating (income) expense, net | **0.1** | (0.2) |
| **Operating income (loss)** | **10.7** | (0.3) |
| Other income (expense), net | **0.3** | (1.6) |
| Interest income, net | **0.3** | 0.3 |
| **Income (loss) before income taxes** | **11.3** | (1.6) |
| Income tax (benefit) expense | **6.8** | (0.2) |
| **Net income (loss)** | $**4.5** | $(1.4) |
| **Basic earnings (loss) per share** | $**0.25** | $(0.08) |
| **Diluted earnings (loss) per share** | $**0.25** | $(0.08) |
| Shares used in computing: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic earnings (loss) per share | **17.8** | 18.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Diluted earnings (loss) per share | **17.9** | 18.5 |

---

*The accompanying notes are an integral part of the condensed consolidated financial statements.*

*4*

------

**ROGERS CORPORATION**

**CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)**

*(Unaudited)*

*(Dollars in millions)* 

---

| | | |
|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** |
| | **March 31, 2026** | March 31, 2025 |
| Net income (loss) | $**4.5** | $(1.4) |
| Foreign currency translation adjustment | **(8.0)** | 17.6 |
| Pension and other post-retirement benefits: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization of loss, net of tax (Note 2) | **0.1** | 0.1 |
| Other comprehensive income (loss) | **(7.9)** | 17.7 |
| Comprehensive income (loss) | $**(3.4)** | $16.3 |

---

*The accompanying notes are an integral part of the condensed consolidated financial statements.*

*5*

------

**ROGERS CORPORATION**

**CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION**

*(Unaudited)*

*(Dollars and shares in millions, except par value*)

---

| | | |
|:---|:---|:---|
| | **March 31, 2026** | December 31, 2025 |
| **Assets** |  |  |
| &nbsp;&nbsp;&nbsp;Current assets |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | $**195.8** | $197.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable, net | **142.1** | 130.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Contract assets | **25.9** | 27.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventories, net | **127.5** | 125.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Asbestos-related insurance recoverables, current portion | **4.7** | 4.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other current assets | **15.4** | 14.8 |
| &nbsp;&nbsp;&nbsp;Total current assets | **511.4** | 500.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Property, plant and equipment, net | **363.9** | 372.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating lease right-of-use assets | **18.5** | 19.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Goodwill | **301.2** | 303.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Intangible assets, net of accumulated amortization | **95.8** | 99.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Asbestos-related insurance recoverables, non-current portion | **48.1** | 48.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred income taxes | **67.8** | 67.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other long-term assets | **19.8** | 20.5 |
| &nbsp;&nbsp;&nbsp;Total assets | $**1426.5** | $1429.9 |
| **Liabilities and Shareholders' Equity** |  |  |
| &nbsp;&nbsp;&nbsp;Current liabilities |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | $**52.8** | $42.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued employee benefits and compensation | **37.1** | 43.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued income taxes payable | **9.9** | 10.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating lease obligations, current portion | **4.0** | 3.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Asbestos-related liabilities, current portion | **5.5** | 5.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other accrued liabilities | **18.0** | 20.4 |
| &nbsp;&nbsp;&nbsp;Total current liabilities | **127.3** | 126.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating lease obligations, non-current portion | **17.5** | 17.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Asbestos-related liabilities, non-current portion | **51.8** | 51.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Non-current income tax | **5.0** | 4.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred income taxes | **17.5** | 17.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other long-term liabilities | **14.7** | 15.8 |
| &nbsp;&nbsp;&nbsp;**Commitments and contingencies (Note 6 and Note 10)** |  |  |
| &nbsp;&nbsp;&nbsp;Shareholders' equity |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Capital stock - $1 par value; 50.0 authorized shares; 17.8 and 17.8 shares issued and outstanding | **17.8** | 17.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additional paid-in capital | **106.1** | 105.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Retained earnings | **1123.8** | 1119.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accumulated other comprehensive loss | **(55.0)** | (47.1) |
| &nbsp;&nbsp;&nbsp;Total shareholders' equity | **1192.7** | 1195.7 |
| &nbsp;&nbsp;&nbsp;Total liabilities and shareholders' equity | $**1426.5** | $1429.9 |

---

*The accompanying notes are an integral part of the condensed consolidated financial statements.*

*6*

------

**ROGERS CORPORATION**

**CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY**

*(Unaudited)*

*(Dollars and shares in millions)*

---

| | | |
|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** |
| | **March 31, 2026** | March 31, 2025 |
| **Capital Stock** |  |  |
| Balance, beginning of period | $**17.8** | $18.5 |
| &nbsp;&nbsp;&nbsp;Balance, end of period | **17.8** | 18.5 |
| **Additional Paid-In Capital** |  |  |
| Balance, beginning of period | **105.7** | 147.3 |
| Shares issued for vested restricted stock units, net of shares withheld for taxes | **(1.3)** | (1.2) |
| Equity compensation expense | **1.7** | 3.6 |
| &nbsp;&nbsp;&nbsp;Balance, end of period | **106.1** | 149.7 |
| **Retained Earnings** |  |  |
| Balance, beginning of period | **1119.3** | 1181.1 |
| Net income (loss) | **4.5** | (1.4) |
| &nbsp;&nbsp;&nbsp;Balance, end of period | **1123.8** | 1179.7 |
| **Accumulated Other Comprehensive Loss** |  |  |
| Balance, beginning of period | **(47.1)** | (95.3) |
| Other comprehensive income (loss) | **(7.9)** | 17.7 |
| &nbsp;&nbsp;&nbsp;Balance, end of period | **(55.0)** | (77.6) |
| **Total Shareholders' Equity** | $**1192.7** | $1270.3 |

---

*The accompanying notes are an integral part of the condensed consolidated financial statements.*

*7*

------

**ROGERS CORPORATION**

**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**

*(Unaudited)*

*(Dollars in millions)*

---

| | | |
|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** |
| | **March 31, 2026** | March 31, 2025 |
| **Operating Activities:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income (loss) | $**4.5** | $(1.4) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adjustments to reconcile net income to cash provided by operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | **13.4** | 12.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Equity compensation expense | **1.7** | 3.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred income taxes | **(0.8)** | (4.6) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Impairment charges | **0.2** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Changes in assets and liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable | **(12.6)** | (1.9) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Contract assets | **1.6** | (0.6) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventories, net | **(3.4)** | 1.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other current assets | **(0.7)** | (0.4) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable and other accrued expenses | **8.1** | 4.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other, net | **(6.2)** | (1.1) |
| Net cash provided by operating activities | **5.8** | 11.7 |
| **Investing Activities:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Capital expenditures | **(4.7)** | (9.6) |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds from the sale of marketable equity securities | **0.3** | 0.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;Purchases of marketable equity securities | **(0.1)** | (0.1) |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds from the sale of property, plant and equipment, net | **—** | 13.4 |
| Net cash provided by (used in) investing activities | **(4.5)** | 3.9 |
| **Financing Activities:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Payments of finance lease obligations | **(0.3)** | (0.4) |
| &nbsp;&nbsp;&nbsp;&nbsp;Payments of taxes related to net share settlement of equity awards | **(1.3)** | (1.2) |
| Net cash used in financing activities | **(1.6)** | (1.6) |
| Effect of exchange rate fluctuations on cash | **(0.9)** | 1.8 |
| **Net increase (decrease) in cash and cash equivalents** | **(1.2)** | 15.8 |
| **Cash and cash equivalents at beginning of period** | **197.0** | 159.8 |
| **Cash and cash equivalents at end of period** | $**195.8** | $175.6 |
| **Supplemental Disclosures:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued capital additions | $**3.8** | $5.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash paid during the year for: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest, net of amounts capitalized | $**0.3** | $0.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income taxes, net of refunds | $**8.0** | $7.7 |

---

*The accompanying notes are an integral part of the condensed consolidated financial statements.*

*8*

------

**ROGERS CORPORATION**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

***(Unaudited)***

**Note 1 – Basis of Presentation**

As used herein, the terms "Company," "Rogers," "we," "us," "our" and similar terms mean Rogers Corporation and its consolidated subsidiaries, unless the context indicates otherwise.

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. GAAP for interim financial information. Accordingly, these statements do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In our opinion, the accompanying condensed consolidated financial statements include all normal recurring adjustments necessary for their fair presentation in accordance with U.S. GAAP. All intercompany balances and transactions have been eliminated.

Interim results are not necessarily indicative of results for a full year. For further information regarding our accounting policies, refer to the audited consolidated financial statements and footnotes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2025 (the "Annual Report").

**Note 2 – Accumulated Other Comprehensive Loss**

The changes in accumulated other comprehensive loss by component were as follows:

---

| | | | |
|:---|:---|:---|:---|
| *(Dollars in millions)* | **Foreign Currency Translation Adjustments** | **Pension and Other Postretirement Benefits**<sup>(1)</sup> | **Total** |
| **Balance as of December 31, 2025** | $**(39.5)** | $**(7.6)** | $**(47.1)** |
| &nbsp;&nbsp;&nbsp;&nbsp;**Other comprehensive loss before reclassifications** | **(8.0)** | **—** | **(8.0)** |
| &nbsp;&nbsp;&nbsp;&nbsp;**Amounts reclassified from accumulated other comprehensive loss** | **—** | **0.1** | **0.1** |
| **Other comprehensive income (loss)** | **(8.0)** | **0.1** | **(7.9)** |
| **Balance as of March 31, 2026** | $**(47.5)** | $**(7.5)** | $**(55.0)** |
| Balance as of December 31, 2024 | $(86.7) | $(8.6) | $(95.3) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other comprehensive income before reclassifications | 17.6 |  | 17.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;Amounts reclassified from accumulated other comprehensive loss |  | 0.1 | 0.1 |
| Other comprehensive income | 17.6 | 0.1 | 17.7 |
| Balance as of March 31, 2025 | $(69.1) | $(8.5) | $(77.6) |

---

<sup>(1)</sup> Net of taxes of $1.2 million as of March 31, 2026 and December 31, 2025. Net of taxes of $1.5 million as of March 31, 2025 and December 31, 2024.

**Note 3 – Derivatives and Hedging**

The valuation of our derivative contracts used to manage their respective risks is described below:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*• Foreign Currency* – The fair value of any foreign currency option derivative is based upon valuation models applied to current market information such as strike price, spot rate, maturity date and volatility, and by reference to market values resulting from an over-the-counter market or obtaining market data for similar instruments with similar characteristics.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*• Commodity* – The fair value of copper derivatives is computed using a combination of intrinsic and time value valuation models, which are collectively a function of five primary variables: price of the underlying instrument, time to expiration, strike price, interest rate and volatility. The intrinsic valuation model reflects the difference between the strike price of the underlying copper derivative instrument and the current prevailing copper prices in an over-the-counter market at period end. The time value valuation model incorporates changes in the price of the underlying copper derivative instrument, the time value of money, the underlying copper derivative instrument's strike price and the remaining time to the underlying copper derivative instrument's expiration date from the period end date.

As of March 31, 2026, we did not have any derivative contracts that qualified for hedge accounting treatment.

------

***Foreign Currency***

During the three months ended March 31, 2026, we entered into U.S. dollar and euro forward contracts. We entered into these foreign currency forward contracts to mitigate certain global transactional exposures. These contracts do not qualify for hedge accounting treatment. As a result, any fair value adjustments required on these contracts are recorded in the "Other income (expense), net" line item in our condensed consolidated statements of operations in the period in which the adjustment occurred.

As of March 31, 2026, the notional values of the remaining foreign currency forward contracts were as follows:

---

| | | |
|:---|:---|:---|
| *(Amounts in millions)* |  |  |
| **Currencies (Buy/Sell)** | **Maturity Date** | **Notional Amount (Buy/Sell)** |
| USD/CNY | May 7, 2026 | $50.8 / ¥352.0 |
| EUR/USD | May 4, 2026 | €16.5 / $19.0 |

---

***Commodity***

As of March 31, 2026, we had 12 outstanding contracts to hedge exposure related to the commodity price of copper in our AES operating and reportable segment. These contracts are held with financial institutions and are intended to offset rising copper prices and do not qualify for hedge accounting treatment. As a result, any fair value adjustments required on these contracts are recorded in the "Other income (expense), net" line item in our condensed consolidated statements of operations in the period in which the adjustment occurred.

As of March 31, 2026, the volume of our copper contracts outstanding was as follows:

---

| | | |
|:---|:---|:---|
| *(Volume in ones, notional in millions)* |  |  |
| **Contract Period** | **Volume** | **Notional Amount** |
| April 2026 - June 2026 | 69 metric tons per month | $2.0 |
| July 2026 - September 2026 | 69 metric tons per month | $2.1 |
| October 2026 - December 2026 | 69 metric tons per month | $2.3 |
| January 2027 - March 2027 | 69 metric tons per month | $2.7 |

---

***Effects on Financial Statements***

The following table presents the impact from these instruments on the consolidated statements of operations and consolidated statements of comprehensive income:

---

| | | | |
|:---|:---|:---|:---|
| | | **Three Months Ended** | **Three Months Ended** |
| *(Dollars in millions)* | **Financial Statement Line Item** | **March 31, 2026** | March 31, 2025 |
| **Foreign Currency Contracts** |  |  |  |
| Contracts not designated as hedging instruments | Other income (expense), net | $**(1.0)** | $(0.2) |

---

**Note 4 - Balance Sheet Items**

***Accounts Receivable***

The "Accounts receivable, net" line item in the condensed consolidated statements of financial position consisted of the following:

---

| | | |
|:---|:---|:---|
| *(Dollars in millions)* | **March 31, 2026** | December 31, 2025 |
| Accounts receivable - trade | $**131.6** | $121.2 |
| Allowance for credit losses | **(1.2)** | (1.3) |
| Accounts receivable - other | **11.7** | 10.7 |
| Total accounts receivable, net | $**142.1** | $130.6 |

---

------

***Contract Assets***

We had contract assets primarily related to unbilled revenue for products that are deemed to have no alternative use whereby we have the right to payment. Revenue is recognized in advance of billing to the customer in these circumstances as billing is typically performed at the time of shipment to the customer. The unbilled revenue is included in the "Contract assets" line item in the condensed consolidated statements of financial position. We did not have any contract liabilities as of March 31, 2026 or December 31, 2025. No impairment losses were recognized in either of the three-month periods ended March 31, 2026 or March 31, 2025 on any contract assets arising from our contracts with customers. Our contract assets by operating segment as of March 31, 2026 and December 31, 2025 were as follows:

---

| | | |
|:---|:---|:---|
| *(Dollars in millions)* | **March 31, 2026** | December 31, 2025 |
| Advanced Electronics Solutions | $**22.2** | $24.0 |
| Elastomeric Material Solutions | **0.1** | 0.1 |
| Other | **3.6** | 3.8 |
| Total contract assets | $**25.9** | $27.9 |

---

***Inventories***

The "Inventories, net" line item in the condensed consolidated statements of financial position consisted of the following:

---

| | | |
|:---|:---|:---|
| *(Dollars in millions)* | **March 31, 2026** | December 31, 2025 |
| Raw materials | $**54.9** | $51.9 |
| Work-in-process | **42.7** | 42.3 |
| Finished goods | **29.9** | 30.8 |
| Total inventories | $**127.5** | $125.0 |

---

***Accounts Payable***

The "Accounts payable" line item in the condensed consolidated statements of financial position consisted of the following:

---

| | | |
|:---|:---|:---|
| *(Dollars in millions)* | **March 31, 2026** | December 31, 2025 |
| Accounts payable - trade | $**52.0** | $41.3 |
| Accounts payable - other | **0.8** | 1.6 |
| Total accounts payable | $**52.8** | $42.9 |

---

**Note 5 - Leases**

***Finance Leases***

We have finance leases primarily related to manufacturing equipment. Noncash activities involving finance lease right-of-use assets obtained in exchange for lease liabilities were nil and $8.1 million for the three months ended March 31, 2026 and 2025, respectively. Our expenses and payments for finance leases were as follows:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** |
| *(Dollars in millions)* | **March 31, 2026** | March 31, 2025 |
| Amortization expense of finance lease right-of-use assets | $**0.4** | $0.3 |
| Interest expense on finance lease obligations | $**(0.1)** | $(0.1) |
| Payments on finance lease obligations | $**0.3** | $0.4 |

---

***Operating Leases***

We have operating leases primarily related to manufacturing and R&D facilities, as well as vehicles. Noncash activities involving operating lease right-of-use assets obtained in exchange for lease liabilities were $0.6 million and $0.2 million for the three months ended March 31, 2026 and 2025, respectively. Our expenses and payments for operating leases were as follows:

------

---

| | | |
|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** |
| *(Dollars in millions)* | **March 31, 2026** | March 31, 2025 |
| Operating leases expense | $**1.3** | $1.5 |
| Short-term leases expense | $**0.1** | $0.2 |
| Payments on operating lease obligations | $**1.2** | $1.1 |

---

***Lease Balances in the Statements of Financial Position***

The assets and liabilities balances related to finance and operating leases reflected in the condensed consolidated statements of financial position were as follows:

---

| | | | |
|:---|:---|:---|:---|
| *(Dollars in millions)* | **Financial Statement Line Item** | **March 31, 2026** | December 31, 2025 |
| Finance lease right-of-use assets | Property, plant and equipment, net | $**8.1** | $8.6 |
| Operating lease right-of-use assets | Operating lease right-of-use assets | $**18.5** | $19.2 |
| Finance lease obligations, current portion | Other accrued liabilities | $**1.4** | $1.4 |
| Finance lease obligations, non-current portion | Other long-term liabilities | $**6.9** | $7.4 |
| **Total finance lease obligations** |  | $**8.3** | $8.8 |
| Operating lease obligations, current portion | Operating lease obligations, current portion | $**4.0** | $3.9 |
| Operating lease obligations, non-current portion | Operating lease obligations, non-current portion | $**17.5** | $17.9 |
| **Total operating lease obligations** |  | $**21.5** | $21.8 |

---

***Net Future Minimum Lease Payments***

The following table includes future minimum lease payments under finance and operating leases together with the present value of the net future minimum lease payments as of March 31, 2026:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Finance** | **Operating** | **Operating** | **Operating** |
| *(Dollars in millions)* | **Leases in Effect** | **Leases Signed** | **Less: Leases Not Yet Commenced** | **Leases in Effect** |
| 2026 | $1.3 | $4.1 | $— | $4.1 |
| 2027 | 1.5 | 4.6 | (0.1) | 4.5 |
| 2028 | 1.4 | 3.4 |  | 3.4 |
| 2029 | 1.4 | 3.2 |  | 3.2 |
| 2030 | 1.3 | 3.1 |  | 3.1 |
| Thereafter | 2.7 | 7.9 |  | 7.9 |
| Total lease payments | 9.6 | 26.3 | (0.1) | 26.2 |
| Less: Interest | (1.3) | (4.7) |  | (4.7) |
| Present Value of Future Minimum Lease Payments | $8.3 | $21.6 | $(0.1) | $21.5 |

---

There were no executed finance leases with future commencement dates as of March 31, 2026.

The following table includes information regarding the lease term and discount rates utilized in the calculation of the present value of net future minimum lease payments:

---

| | | |
|:---|:---|:---|
| | **March 31, 2026** | December 31, 2025 |
| **Weighted Average Remaining Lease Term** |  |  |
| &nbsp;&nbsp;Finance leases | **6.4 years** | 6.7 years |
| &nbsp;&nbsp;Operating leases | **6.2 years** | 6.4 years |
| **Weighted Average Discount Rate** |  |  |
| &nbsp;&nbsp;Finance leases | **4.71%** | 4.70% |
| &nbsp;&nbsp;Operating leases | **5.50%** | 5.55% |

---

------

**Note 6 – Goodwill and Intangible Assets**

***Goodwill***

The changes in the net carrying amount of goodwill by operating segment were as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| *(Dollars in millions)* | **Advanced Electronics Solutions** | **Elastomeric Material Solutions** | **Other** | **Total** |
| December 31, 2025 | $51.7 | $249.5 | $2.2 | $303.4 |
| Foreign currency translation adjustment |  | (2.2) |  | (2.2) |
| **March 31, 2026** | $**51.7** | $**247.3** | $**2.2** | $**301.2** |

---

***Intangible Assets***

The carrying amount of intangible assets were as follows:

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | **March 31, 2026** | **March 31, 2026** | **March 31, 2026** | December 31, 2025 | December 31, 2025 | December 31, 2025 | December 31, 2025 |
| *(Dollars in millions)* | **Gross Carrying Amount** | **Accumulated Amortization** | **Net Carrying Amount** | Gross Carrying Amount | Accumulated Impairment | Accumulated Amortization | Net Carrying Amount |
| Customer relationships | $**179.8** | $**106.9** | $**72.9** | $180.9 | $— | $105.6 | $75.3 |
| Technology | **78.7** | **67.2** | **11.5** | 79.4 |  | 67.2 | 12.2 |
| Trademarks and trade names | **19.8** | **8.4** | **11.4** | 20.1 |  | 8.3 | 11.8 |
| Total definite-lived intangible assets | **278.3** | **182.5** | **95.8** | 280.4 |  | 181.1 | 99.3 |
| Indefinite-lived intangible asset | **—** | **—** | **—** | 4.5 | 4.5 |  |  |
| Total intangible assets | $**278.3** | $**182.5** | $**95.8** | $284.9 | $4.5 | $181.1 | $99.3 |

---

In the table above, gross carrying amounts and accumulated amortization may differ from prior periods due to foreign exchange rate fluctuations.

The amortization expense related to intangible assets was as follows:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** |
| *(Dollars in millions)* | **March 31, 2026** | March 31, 2025 |
| Amortization expense | $**2.7** | $2.7 |

---

The estimated future amortization expense is $8.0 million, $10.2 million, $8.0 million, $7.5 million, and $7.1 million in 2026, 2027, 2028, 2029, and 2030, respectively. These amounts could vary based on changes in foreign currency exchange rates.

The weighted average amortization period as of March 31, 2026, by intangible asset class, is presented in the table below:

---

| | |
|:---|:---|
| | **Weighted Average Remaining Amortization Period** |
| Customer relationships | 6.6 years |
| Technology | 2.6 years |
| Trademarks and trade names | 8.5 years |
| Total intangible assets | **6.3 years** |

---

**Note 7 – Postretirement Benefit Plans**

***Pension Plan***

As of March 31, 2026, we had one qualified noncontributory defined benefit pension plan, the Union Plan, which was frozen and ceased accruing benefits in 2013. The measurement date is December 31<sup>st</sup> for each respective plan year. We were not required to make any contributions to the Union Plan in 2025 and will not be required to make any contributions in 2026.

------

***Deferred Compensation Plan***

We sponsor a non-qualified deferred compensation plan, which provides specified deferred compensation benefits to a certain group of select employees. The deferred compensation plan is funded through a rabbi trust, which is ultimately invested in accordance with each plan participants' selections from pre-approved funds. As of March 31, 2026 and December 31, 2025, our deferred compensation plan primarily consisted of marketable securities, which includes mutual funds and fixed income funds. Marketable securities are recorded at fair value. The balances are reflected in the "Other long-term assets" line item in the condensed consolidated statements of financial position. The following table summarizes, by major security type, our marketable securities that are measured at fair value on a recurring basis and are categorized using the fair value hierarchy:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Fair Value of Deferred Compensation Plan as of March 31, 2026** | **Fair Value of Deferred Compensation Plan as of March 31, 2026** | **Fair Value of Deferred Compensation Plan as of March 31, 2026** | **Fair Value of Deferred Compensation Plan as of March 31, 2026** |
| *(Dollars in millions)* | **Adjusted Cost** | **Unrealized Gains** | **Unrealized Losses** | **Fair Value** |
| **Level 1 Securities:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;**Mutual funds** | $**3.9** | $**0.6** | $**(0.1)** | $**4.4** |
| **Level 2 Securities:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;**Fixed income funds** | $**0.1** | $**—** | $**—** | $**0.1** |
| **Total** | $**4.0** | $**0.6** | $**(0.1)** | $**4.5** |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| | Fair Value of Deferred Compensation Plan as of December 31, 2025 | Fair Value of Deferred Compensation Plan as of December 31, 2025 | Fair Value of Deferred Compensation Plan as of December 31, 2025 | Fair Value of Deferred Compensation Plan as of December 31, 2025 |
| *(Dollars in millions)* | Adjusted Cost | Unrealized Gains | Unrealized Losses | Fair Value |
| Level 1 Securities: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Mutual funds | $4.1 | $0.7 | $(0.1) | $4.7 |
| Level 2 Securities: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Fixed income funds | $0.1 | $— | $— | $0.1 |
| Total | $4.2 | $0.7 | $(0.1) | $4.8 |

---

**Note 8 – Revolving Credit Facility** 

On March 24, 2023, the Company entered into a Fifth Amended and Restated Credit Agreement that provides for a $450.0 million revolving credit facility, with an expansion feature of up to $225.0 million, and which matures on March 24, 2028. The material terms of the Fifth Amended and Restated Credit Agreement are described in Note 9 to the consolidated financial statements included in the Company's Annual Report. There have been no material changes to the terms of the Credit Agreement during the three months ended March 31, 2026.

As of March 31, 2026 and December 31, 2025, the Company had no borrowings outstanding under the revolving credit facility and was in compliance with all financial and non-financial covenants.

**Note 9 – Commitments and Contingencies**

We are currently engaged in the following material legal and environmental proceedings:

***Asbestos***

*Overview*

We, like many other industrial companies, have been named as a defendant in a number of lawsuits filed in courts across the country by persons alleging personal injury from exposure to products containing asbestos. We have never mined, milled, manufactured or marketed asbestos; rather, we made and provided to industrial users a limited number of products that contained encapsulated asbestos, but we stopped manufacturing these products in the late 1980s. Most of the claims filed against us involve numerous defendants, sometimes as many as several hundred. In virtually all of the cases against us, the plaintiffs are seeking unspecified damages above a jurisdictional minimum against multiple defendants who may have manufactured, sold or used asbestos-containing products to which the plaintiffs were allegedly exposed and from which they purportedly suffered injury. Most of these cases are being litigated in Maryland, Illinois, Missouri and New York; however, we are also defending cases in other states. We continue to vigorously defend these cases, primarily on the basis of the plaintiffs' inability to establish compensable loss as a result of exposure to our products. The indemnity and defense costs of our asbestos-related product liability litigation to date have been substantially covered by insurance.

------

The following table summarizes the change in number of asbestos claims outstanding for the three months ended March 31, 2026:

---

| | |
|:---|:---|
| | **Asbestos Claims** |
| Claims outstanding as of January 1, 2026 | 442 |
| New claims filed | 45 |
| Pending claims dismissed | (61) |
| Pending claims settled | (6) |
| **Claims outstanding as of March 31, 2026** | **420** |

---

The total indemnity settlements for asbestos claims were immaterial as of March 31, 2026.

*Impact on Financial Statements*

We recognize a liability for asbestos-related contingencies that are probable of occurrence and reasonably estimable. In connection with the recognition of liabilities for asbestos-related matters, we record asbestos-related insurance recoverables that are deemed probable.

The liability projection period covers all current and future indemnity and defense costs through 2064, which represents the expected end of our asbestos liability exposure with no further ongoing claims expected beyond that date. This conclusion was based on our history and experience with the claims data, the diminished volatility and consistency of observable claims data, the period of time that has elapsed since we stopped manufacturing products that contained encapsulated asbestos and an expected downward trend in claims due to the average age of our claimants, which is approaching the average life expectancy.

To date, the indemnity and defense costs of our asbestos-related product liability litigation have been substantially covered by insurance. Although we have exhausted coverage under some of our insurance policies, we believe that we have applicable primary, excess and/or umbrella coverage for claims arising with respect to most of the years during which we manufactured and marketed asbestos-containing products. In addition, we have entered into a cost sharing agreement with most of our primary, excess and umbrella insurance carriers to facilitate the ongoing administration and payment of claims covered by the carriers. The cost sharing agreement may be terminated by any party, but will continue until a party elects to terminate it. As of the filing date for this report, the agreement has not been terminated, and no carrier has informed us that it intends to terminate the agreement. We expect to continue to exhaust individual primary, excess and umbrella coverages over time, and there is no assurance that such exhaustion will not accelerate due to additional claims, damages and settlements or that coverage will be available as expected.

The amounts recorded for the asbestos-related liability and the related insurance recoverables are based on facts known at the time and a number of assumptions. However, projecting future events, such as the number of new claims to be filed each year, the average cost of disposing of such claims, the length of time it takes to dispose of such claims, coverage issues among insurers and the continuing solvency of various insurance companies, as well as the numerous uncertainties surrounding asbestos litigation in the U.S., could cause the actual liability and insurance recoveries for us to be higher or lower than those projected or recorded. The full extent of our financial exposure to asbestos-related litigation remains very difficult to estimate and could include both compensatory and punitive damage awards.

Changes recorded in the estimated liability and estimated insurance recovery based on projections of asbestos litigation and corresponding insurance coverage, result in the recognition of expense or income.

Our projected asbestos-related liabilities and insurance recoverables were as follows:

---

| | | |
|:---|:---|:---|
| *(Dollars in millions)* | **March 31, 2026** | December 31, 2025 |
| Asbestos-related liabilities | $**57.3** | $57.4 |
| Asbestos-related insurance recoverables | $**52.8** | $52.8 |

---

***Environmental Voluntary Corrective Action Program***

Our location in Rogers, Connecticut is part of the Connecticut Voluntary Corrective Action Program. As part of this program, we partnered with the Connecticut Department of Energy and Environmental Protection to determine the corrective actions to be taken at the site related to contamination issues. We evaluated this matter and completed internal due diligence work related to the site in 2015. Remediation activities on the site are ongoing and are recorded as reductions to the accrual as they are incurred. We have incurred $2.0 million of aggregate remediation costs through March 31, 2026, substantially all of which was incurred and accrued for prior to 2023, and the accrual for future remediation efforts is $0.7 million.

------

***Other Matters***

In addition to the above issues, the nature and scope of our business brings us in regular contact with the general public and a variety of businesses and government agencies. Such activities inherently subject us to the possibility of litigation, including environmental and product liability matters that are defended and handled in the ordinary course of business. We have established accruals for matters for which management considers a loss to be probable and reasonably estimable. It is the opinion of management that facts known at the present time do not indicate that such litigation will have a material adverse impact on our results of operations, financial position or cash flows.

**Note 10 – Earnings (Loss) Per Share**

Basic earnings (loss) per share is based on the weighted average number of common shares outstanding. Diluted earnings (loss) per share is based on the weighted average number of common shares outstanding and all dilutive potential common shares outstanding.

The following table sets forth the computation of basic and diluted earnings (loss) per share:

---

| | | |
|:---|:---|:---|
| *(Dollars and shares in millions, except per share amounts)* | **Three Months Ended** | **Three Months Ended** |
| *(Dollars and shares in millions, except per share amounts)* | **March 31, 2026** | March 31, 2025 |
| Numerator: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income (loss) | $**4.5** | $(1.4) |
| Denominator: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Weighted-average shares outstanding - basic | **17.8** | 18.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;Effect of dilutive shares | **0.1** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Weighted-average shares outstanding - diluted | **17.9** | 18.5 |
| Basic earnings (loss) per share | $**0.25** | $(0.08) |
| Diluted earnings (loss) per share | $**0.25** | $(0.08) |

---

Dilutive shares are calculated using the treasury stock method and primarily include unvested restricted stock units. Anti-dilutive shares are excluded from the calculation of diluted shares and diluted earnings per share. For the three months ended March 31, 2026, an immaterial number of shares were excluded from the calculation of diluted earnings per share.

For the three months ended March 31, 2025, the assumed vesting of restricted stock units had an antidilutive effect on diluted loss per share and were excluded from the calculation of diluted loss per share. For the three months ended March 31, 2025, 0.2 million anti-dilutive shares were excluded from the calculation of diluted loss per share.

**Note 11 – Capital Stock and Equity Compensation**

***Equity Compensation***

*Equity Compensation Expense*

The components of equity compensation expense were as follows:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** |
| *(Dollars in millions)* | **March 31, 2026** | March 31, 2025 |
| Performance-based restricted stock units expense | $**—** | $1.8 |
| Time-based restricted stock units expense | **1.3** | 1.7 |
| Deferred stock units expense | **0.3** | 0.1 |
| Other | **0.1** |  |
| Total equity compensation expense | $**1.7** | $3.6 |

---

*Performance-Based Restricted Stock Units*

As of March 31, 2026, we had outstanding performance-based restricted stock units with a market condition from 2026, 2025 and 2024. These awards generally cliff vest at the end of a three-year measurement period. However, employees whose employment terminates during the measurement period due to death, disability, or, in certain cases, retirement may receive a pro-rata payout based on the number of days they were employed during the measurement period. Participants are eligible to be awarded shares ranging from 0% to 200% of the original award amount, based on certain defined performance measures.

The performance-based restricted stock units with a market condition have one measurement criterion: the three-year total shareholder return on our capital stock as compared to that of a specified group of peer companies. The fair value of this measurement criterion was determined on the grant date using a Monte Carlo simulation valuation model. We recognize

------

compensation expense on all of these awards on a straight-line basis over the vesting period with no changes for final projected payout of the awards. We account for forfeitures as they occur.

The following table sets forth the assumptions used in the Monte Carlo calculation for each material award granted in 2026 and 2025:

---

| | | | |
|:---|:---|:---|:---|
| | **February 18, 2026** | **February 12, 2026** | February 26, 2025 |
| Expected volatility | **34.7%** | **34.6%** | 45.6% |
| Expected term (in years) | **2.9 years** | **2.9 years** | 2.9 years |
| Risk-free interest rate | **3.44%** | **3.43%** | 4.28% |

---

Expected volatility – In determining expected volatility, we have considered a number of factors, including historical volatility.

Expected term – We use the vesting period of the award to determine the expected term assumption for the Monte Carlo simulation valuation model.

Risk-free interest rate – We use an implied "spot rate" yield on U.S. Treasury Constant Maturity rates as of the grant date for our assumption of the risk-free interest rate.

Expected dividend yield – We do not currently pay dividends on our capital stock; therefore, a dividend yield of 0% was used in the Monte Carlo simulation valuation model.

As of March 31, 2026, we had outstanding performance-based restricted stock units with a financial performance condition granted in 2026. These awards are subject to a three-year performance period covering January 1, 2026 through December 31, 2028 and generally vest, if at all, following the completion of the performance period. Employees whose employment terminates during the performance period due to death, disability, or, in certain cases, qualified retirement may be eligible to receive a pro-rata payout based on the number of days employed during the performance period.

The performance-based restricted stock units with a financial performance condition have one performance criterion: annual net sales growth, measured over the three-year performance period, with the final payout determined based on the average payout level achieved for each year. The fair value of these awards was determined based on the market value of the Company's common stock on the grant date, with cumulative compensation expense recognized to date adjusted based on changes in the estimated payout percentage at the end of each reporting period. As of March 31, 2026, the performance condition was considered probable of achievement. Accordingly, compensation expense has been recognized based on this estimated payout level. The Company accounts for forfeitures as they occur.

A summary of activity of the outstanding performance-based restricted stock units for the three months ended March 31, 2026 is presented below:

---

| | |
|:---|:---|
| | **Performance-Based<br>Restricted Stock Units** |
| Awards outstanding as of December 31, 2025 | 109916 |
| &nbsp;&nbsp;&nbsp;&nbsp;Awards granted | 39560 |
| &nbsp;&nbsp;&nbsp;&nbsp;Stock issued |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Awards forfeited/cancelled | (56599) |
| Awards outstanding as of March 31, 2026 | **92877** |

---

*Time-Based Restricted Stock Units*

As of March 31, 2026, we had time-based restricted stock unit awards from 2026, 2025 and 2024 outstanding. The outstanding awards all ratably vest on the first, second and third anniversaries of the original grant date. However, employees whose employment terminates during the measurement period due to death, disability, or, in certain cases, retirement may receive a pro-rata payout based on the number of days they were employed subsequent to the last grant anniversary date. Each time-based restricted stock unit represents a right to receive one share of Rogers' capital stock at the end of the vesting period. The fair value of the award is determined by the market value of the underlying stock price on the grant date. We recognize compensation expense on all of these awards on a straight-line basis over the vesting period. We account for forfeitures as they occur.

------

A summary of activity of the outstanding time-based restricted stock units for the three months ended March 31, 2026 is presented below:

---

| | |
|:---|:---|
| | **Time-Based<br>Restricted Stock Units** |
| Awards outstanding as of December 31, 2025 | 115905 |
| &nbsp;&nbsp;&nbsp;&nbsp;Awards granted | 53307 |
| &nbsp;&nbsp;&nbsp;&nbsp;Stock issued | (40457) |
| &nbsp;&nbsp;&nbsp;&nbsp;Awards forfeited/cancelled | (17306) |
| Awards outstanding as of March 31, 2026 | **111449** |

---

*Deferred Stock Units*

We grant deferred stock units to non-management directors. These awards will generally vest at the one-year anniversary of the award, subject to continuous service. Each deferred stock unit results in the issuance of one share of Rogers' capital stock. The grant of deferred stock units is typically done annually during the second quarter of each year. The fair value of the award is determined by the market value of the underlying stock price on the grant date.

A summary of activity of the outstanding deferred stock units for the three months ended March 31, 2026 is presented below:

---

| | |
|:---|:---|
| | **Deferred Stock Units** |
| Awards outstanding as of December 31, 2025 | 23566 |
| &nbsp;&nbsp;&nbsp;&nbsp;Awards granted |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Stock issued | (536) |
| Awards outstanding as of March 31, 2026 | **23030** |

---

**Note 12 – Segment Information**

Our reporting structure is comprised of the following strategic operating and reportable segments: AES and EMS. The remaining operations, which represent our non-core businesses, are reported in the Other operating segment. This structure aligns our external reporting presentation with how we currently manage and view our business internally. Our CODM is the Chief Executive Officer of Rogers Corporation. The CODM uses gross margin as a reported segment profit or loss measure to evaluate the performance of each business segment and then leverages this information to decide where to allocate resources and assess how well each segment is performing financially, considering factors like revenue, inventory, and significant expenses specific to that segment.

Our AES operating and reportable segment designs, develops, manufactures and sells circuit materials, ceramic substrate materials, busbars and cooling solutions for applications in EV/HEV, automotive (e.g., ADAS), aerospace and defense (e.g., antenna systems, communication systems and phased array radar systems), renewable energy (e.g., wind and solar), wireless infrastructure (e.g., power amplifiers, antennas and small cells), mass transit, industrial (e.g., variable frequency drives), connected devices (e.g., mobile internet devices and thermal solutions) and wired infrastructure (e.g., computing and internet protocol infrastructure) markets.

Our EMS operating and reportable segment designs, develops, manufactures and sells engineered material solutions for a wide variety of applications and markets. These include polyurethane and silicone materials used in cushioning, gasketing and sealing, and vibration management applications for EV/HEV, general industrial, portable electronics, automotive, mass transit, aerospace and defense, footwear and impact mitigation markets; customized silicones used in flex heater and semiconductor thermal applications for EV/HEV, general industrial, portable electronics, automotive, mass transit, aerospace and defense and medical markets; and polytetrafluoroethylene and ultra-high molecular weight polyethylene materials used in wire and cable protection, electrical insulation, conduction and shielding, hose and belt protection, vibration management, cushioning, gasketing and sealing, and venting applications for EV/HEV, general industrial, automotive, and aerospace and defense markets.

Our Other operating segment consists of elastomer components for applications in the general industrial market, as well as elastomer floats for level sensing in fuel tanks, motors, and storage tanks applications in the general industrial and automotive markets.

------

***Segment Information***

The following table presents a disaggregation of revenue from contracts with customers and other pertinent financial information for the periods indicated; inter-segment sales have been eliminated from the net sales data:

---

| | | | | |
|:---|:---|:---|:---|:---|
| *(Dollars in millions)* | **Advanced Electronics Solutions** | **Elastomeric Material Solutions** | **Other** | **Total** |
| **Three Months Ended March 31, 2026** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;**Net sales - recognized over time** | $**39.4** | $**1.5** | $**3.9** | $**44.8** |
| &nbsp;&nbsp;&nbsp;**Net sales - recognized at a point in time** | **68.3** | **86.9** | **0.5** | **155.7** |
| &nbsp;&nbsp;&nbsp;**Total net sales** | $**107.7** | $**88.4** | $**4.4** | $**200.5** |
| &nbsp;&nbsp;&nbsp;**Cost of sales** | $**76.3** | $**57.1** | $**2.5** | $**135.9** |
| &nbsp;&nbsp;&nbsp;**Gross margin** | $**31.4** | $**31.3** | $**1.9** | $**64.6** |
| &nbsp;&nbsp;&nbsp;**Inventories, net** | $**78.7** | $**47.2** | $**1.6** | $**127.5** |
| &nbsp;&nbsp;&nbsp;**Depreciation expense** | $**5.4** | $**2.7** | $**0.2** | $**8.3** |
| Three Months Ended March 31, 2025 |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net sales - recognized over time | $38.9 | $2.1 | $3.5 | $44.5 |
| &nbsp;&nbsp;&nbsp;Net sales - recognized at a point in time | 65.3 | 80.5 | 0.2 | 146.0 |
| &nbsp;&nbsp;&nbsp;Total net sales | $104.2 | $82.6 | $3.7 | $190.5 |
| &nbsp;&nbsp;&nbsp;Cost of sales | $75.1 | $55.9 | $2.5 | $133.5 |
| &nbsp;&nbsp;&nbsp;Gross margin | $29.1 | $26.7 | $1.2 | $57.0 |
| &nbsp;&nbsp;&nbsp;Inventories, net | $80.5 | $60.7 | $1.8 | $143.0 |
| &nbsp;&nbsp;&nbsp;Depreciation expense | $4.2 | $2.8 | $0.2 | $7.2 |

---

------

***Segment Net Sales by Geographic Area***

The following table presents net sales by our segment operations by geographic area for the periods indicated:

---

| | | | | |
|:---|:---|:---|:---|:---|
| *(Dollars in millions)* | **Net Sales**<sup>(1)</sup> | **Net Sales**<sup>(1)</sup> | **Net Sales**<sup>(1)</sup> | **Net Sales**<sup>(1)</sup> |
| Region/Country | **Advanced Electronics Solutions** | **Elastomeric Material Solutions** | **Other** | **Total** |
| **Three Months Ended March 31, 2026** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;**United States** | $**18.7** | $**36.2** | $**0.9** | $**55.8** |
| &nbsp;&nbsp;&nbsp;&nbsp;**Other Americas** | **1.1** | **3.1** | **0.1** | **4.3** |
| &nbsp;&nbsp;&nbsp;**Total Americas** | **19.8** | **39.3** | **1.0** | **60.1** |
| &nbsp;&nbsp;&nbsp;&nbsp;**China** | **39.6** | **20.7** | **1.4** | **61.7** |
| &nbsp;&nbsp;&nbsp;&nbsp;**Other APAC** | **14.0** | **7.7** | **0.5** | **22.2** |
| &nbsp;&nbsp;&nbsp;**Total APAC** | **53.6** | **28.4** | **1.9** | **83.9** |
| &nbsp;&nbsp;&nbsp;&nbsp;**Germany** | **13.4** | **6.4** | **0.2** | **20.0** |
| &nbsp;&nbsp;&nbsp;&nbsp;**Other EMEA** | **20.9** | **14.3** | **1.3** | **36.5** |
| &nbsp;&nbsp;&nbsp;**Total EMEA** | **34.3** | **20.7** | **1.5** | **56.5** |
| &nbsp;&nbsp;&nbsp;**Total net sales** | $**107.7** | $**88.4** | $**4.4** | $**200.5** |
| Three Months Ended March 31, 2025 |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;United States | $22.1 | $33.7 | $0.9 | $56.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other Americas | 0.8 | 3.0 |  | 3.8 |
| &nbsp;&nbsp;&nbsp;Total Americas | 22.9 | 36.7 | 0.9 | 60.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;China | 33.6 | 19.9 | 1.0 | 54.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other APAC | 12.7 | 8.0 | 0.6 | 21.3 |
| &nbsp;&nbsp;&nbsp;Total APAC | 46.3 | 27.9 | 1.6 | 75.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;Germany | 11.6 | 5.6 | 0.2 | 17.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other EMEA | 23.4 | 12.4 | 1.0 | 36.8 |
| &nbsp;&nbsp;&nbsp;Total EMEA | 35.0 | 18.0 | 1.2 | 54.2 |
| &nbsp;&nbsp;&nbsp;Total net sales | $104.2 | $82.6 | $3.7 | $190.5 |

---

<sup>(1)</sup> Net sales are allocated to countries based on the location of the customer. The table above lists individual countries with 10% or more of net sales for the periods indicated.

**Note 13 – Supplemental Financial Information**

***Restructuring and Impairment Charges***

The components of the "Restructuring and impairment charges" line item in the condensed consolidated statements of operations, were as follows:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** |
| *(Dollars in millions)* | **March 31, 2026** | March 31, 2025 |
| Restructuring charges |  |  |
| &nbsp;&nbsp;Manufacturing footprint consolidation | $**4.4** | $4.0 |
| &nbsp;&nbsp;Global workforce reduction | **0.5** | 1.8 |
| &nbsp;&nbsp;Executive leadership transition | **0.8** |  |
| &nbsp;&nbsp;Other | **—** | 0.1 |
| Total restructuring charges | **5.7** | 5.9 |
| Impairment charges |  |  |
| &nbsp;&nbsp;Lease impairment charges | **0.2** |  |
| Total impairment charges | **0.2** |  |
| **Total restructuring and impairment charges** | $**5.9** | $5.9 |

---

------

*Restructuring Charges - Manufacturing Footprint Consolidation*

In June 2024, we announced our intent to consolidate our high frequency circuit material manufacturing operations, impacting our Evergem, Belgium facility, which was completed in the fourth quarter of 2025. We incurred $4.0 million in restructuring charges in the three months ended March 31, 2025, of which $3.2 million related to severance and other termination benefits and $0.7 million related to accelerated depreciation.

In July 2025, we announced our intention to implement initiatives to reduce costs in the curamik<sup>®</sup> business under our AES operating and reportable segment and expect to record expenses in the range of $12.0 million to $15.0 million comprised of severance costs, property plant and equipment relocation and reinstallation costs, consulting fees and other miscellaneous cash costs.

During the three months ended March 31, 2026, we recognized $4.4 million in restructuring charges, nearly all of which relates to severance and termination benefits.

*Restructuring Charges - Global Workforce Reduction*

In 2025, we announced a plan to reduce our global workforce that was substantially completed in the second half of 2025. We incurred $0.5 million and $1.8 million in pre-tax restructuring charges related to this plan for the three months ended March 31, 2026 and 2025, respectively, all of which were related to severance and other termination benefits.

*Restructuring Charges - Executive Leadership Transition*

In July 2025, certain executives left the Company as part of an executive leadership transition. In addition to these departures, other related organizational changes were made leading to departures of additional personnel through March 2026. We have incurred $0.8 million in restructuring charges related to this transition in the three months ended March 31, 2026 for severance and other termination benefits.

*Restructuring Severance and Related Benefits Accrual*

Remaining severance and related benefits to be paid for the manufacturing footprint consolidation, global workforce reduction, and executive leadership transition restructuring projects is presented in the table below for the period ending March 31, 2026:

---

| | |
|:---|:---|
| *(Dollars in thousands)* | **Restructuring Severance and Related Benefits** |
| Balance as of December 31, 2025 | $10.2 |
| Provisions | 5.5 |
| Payments | (7.3) |
| Foreign currency translation adjustment | (0.1) |
| **Balance as of March 31, 2026** | $**8.3** |

---

*Allocation of Restructuring and Impairment Charges to Operating and Reportable Segments*

The following table summarizes the allocation of restructuring and impairment charges to our operating and reportable segments:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** |
| *(Dollars in millions)* | **March 31, 2026** | March 31, 2025 |
| *Advanced Electronics Solutions* |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Allocated restructuring charges | $**5.2** | $4.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;Allocated impairment charges | **0.2** |  |
| *Elastomeric Material Solutions* |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Allocated restructuring charges | **0.5** | 1.2 |
| Total restructuring and impairment charges | $**5.9** | $5.9 |

---

------

***Other Income (Expense), Net***

The components of the "Other income (expense), net" line item in the condensed consolidated statements of operations, were as follows:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** |
| *(Dollars in millions)* | **March 31, 2026** | March 31, 2025 |
| Foreign currency translation impacts | $**1.3** | $(1.3) |
| Foreign currency derivative impacts | **(1.0)** | (0.2) |
| Copper derivative impacts | **—** | 0.2 |
| Other | **—** | (0.3) |
| **Total other income (expense), net** | $**0.3** | $(1.6) |

---

***Interest Income (Expense), Net***

The components of "Interest income (expense), net" line item in the condensed consolidated statements of operations, were as follows:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** |
| *(Dollars in millions)* | **March 31, 2026** | March 31, 2025 |
| Line of credit fees | **(0.3)** | (0.3) |
| Debt issuance amortization costs | **(0.1)** | (0.1) |
| Interest income | **0.8** | 0.8 |
| Other | **(0.1)** | (0.1) |
| **Total interest income (expense), net** | $**0.3** | $0.3 |

---

**Note 14 – Income Taxes**

Compared to the 21% U.S. statutory federal income tax rate, we had a tax rate of 60.2% in the first quarter of 2026. During the quarter, our effective tax rate was unfavorably impacted by an increase in the valuation allowance attributable to loss jurisdictions in which no tax benefit is anticipated to be realized.

We had a tax rate of 12.5% in the first quarter of 2025 when we incurred a loss before income taxes of $1.6 million, which, when taxed at the 21% U.S. statutory federal income tax rate, resulted in an immaterial income tax benefit, partially offset by insignificant tax adjustments that caused the effective tax rate to differ from the statutory rate.

**Note 15 - Recent Accounting Standards**

**Recently Adopted Standards**

In July 2025, the FASB issued ASU 2025-05, *Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets for Private Companies and Certain Not-for-Profit Entities (Subtopic 326-20)*. The amendments in this update provide a practical expedient allowing eligible entities to measure expected credit losses on current trade receivables and contract assets using an aging method, rather than developing a full CECL model. The ASU is effective for fiscal years beginning after December 15, 2025, with early adoption permitted. Adoption should be applied prospectively to financial statements issued after the effective date, or retrospectively to any or all prior periods presented. The updated guidance has not had an impact on how we calculate our allowance for credit losses.

***Recently Issued Standards***

In September 2025, the FASB issued ASU 2025-06, *Intangibles - Goodwill and Other Internal-Use Software (Subtopic 350-40).* This update specifically targets improvements to the accounting for internal-use software. The amendments in this update (1) remove all references to prescriptive and sequential software development stages throughout Subtopic 350-40, (2) specify that the disclosures in Subtopic 360-10 are required for all capitalized internal-use software costs, regardless of how those costs are presented in the financial statements, (3) clarify that the intangibles disclosures in paragraphs 350-30-50-1 through 50-3 are not required for capitalized internal-use software costs, and (4) supersede the website development costs guidance and incorporate the recognition requirements for website-specific development costs from Subtopic 350-50 into Subtopic 350-40. The ASU is effective for fiscal years beginning after December 15, 2027, and interim periods within those annual reporting periods, with early adoption permitted. Adoption should be applied either prospectively to financial statements

------

issued after the effective date, a modified approach that is based on the status of the project and whether software costs were capitalized before the date of adoption, or retrospectively to any or all prior periods presented in the financial statements. We are currently evaluating the potential impact of adopting this guidance on our consolidated financial statements and accompanying notes.

**Item 2.&nbsp;&nbsp;&nbsp;&nbsp;Management's Discussion and Analysis of Results of Operations and Financial Position**

As used herein, the "Company," "Rogers," "we," "us," "our" and similar terms include Rogers Corporation and its subsidiaries, unless the context indicates otherwise.

**Forward-Looking Statements**

This Form 10-Q includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Exchange Act. Such statements are generally accompanied by words such as "anticipate," "assume," "believe," "could," "estimate," "expect," "foresee," "goal," "intend," "may," "might," "plan," "potential," "predict," "project," "should," "seek," "target" or similar expressions that convey uncertainty as to future events or outcomes. Forward-looking statements are based on assumptions and beliefs that we believe to be reasonable; however, assumed facts almost always vary from actual results, and the differences between assumed facts and actual results could be material depending upon the circumstances. Where we express an expectation or belief as to future results, that expectation or belief is expressed in good faith and based on assumptions believed to have a reasonable basis. We cannot assure you, however, that the stated expectation or belief will occur or be achieved or accomplished. Among the factors that could cause our results to differ materially from those indicated by forward-looking statements are risks and uncertainties inherent in our business including, without limitation:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• failure to capitalize on, volatility within, or other adverse changes with respect to growth opportunities, such as delays in adoption or implementation of new technologies;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• uncertain business, economic and political conditions in the U.S. and abroad, particularly in China, Germany, England, Belgium, South Korea and Hungary where we maintain significant manufacturing, sales or administrative operations;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the global trade policy dynamics between nations reflected in trade agreement negotiations, the imposition of tariffs and other trade restrictions, as well as the potential for global supply chain decoupling;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• fluctuations in foreign currency exchange rates;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to develop innovative products and the extent to which they are incorporated into end-user products and systems that achieve commercial success;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the ability and willingness of our sole or limited source suppliers to deliver certain key raw materials, including commodities, to us in a timely and cost-effective manner;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• business interruptions due to catastrophes, geopolitical events, or other similar events, such as natural disasters, war, terrorism or public health crises;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the impact of sanctions, export controls and other foreign asset or investment restriction;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• failure to realize, or delays in the realization of, anticipated benefits of acquisitions and divestitures due to, among other things, the existence of unknown liabilities or difficulty integrating acquired businesses;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to attract and retain management and skilled technical personnel;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to protect our proprietary technology from infringement by third parties and/or allegations that our technology infringes third party rights;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• changes in effective tax rates or tax laws and regulations in the jurisdictions in which we operate;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• failure to comply with financial and restrictive covenants in our credit agreement or restrictions on our operational and financial flexibility due to such covenants;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the outcome of ongoing and future litigation, including our asbestos-related product liability litigation;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• changes in environmental laws and regulations applicable to our business; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• disruptions in, or breaches of, our information technology systems.

Our forward-looking statements are expressly qualified by these cautionary statements, which you should consider carefully, along with the risks discussed in this section and elsewhere in this report in addition to the section entitled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2025 (the Annual Report) and our other reports filed with the SEC, any of which could cause actual results to differ materially from historical results or anticipated results. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, unless required by law.

The following discussion and analysis of our financial condition and results of operations should be read together with our condensed consolidated financial statements and the related notes that appear elsewhere in this Form 10-Q along with our audited consolidated financial statements and the related notes thereto in our Annual Report.

------

**Company Overview and Strategy**

We design, develop, manufacture and sell high-performance and high-reliability engineered materials and components to meet our customers' needs. We operate two strategic operating and reportable segments: AES and EMS. Our remaining operations, which represent non-core businesses, are reported in our Other operating segment. We are headquartered in Chandler, Arizona.

Our growth and profitability strategy is based upon the following principles: (1) market-driven organization, (2) innovation leadership, (3) operational excellence, and (4) synergistic mergers and acquisitions. Our priorities in executing this strategy are focused on driving near-term improvements to profitability and improving the growth outlook for the Company over the next several years by further strengthening our focus on commercial activities, optimizing our global capacity to meet customer demand and driving innovation.

As a market-driven organization, we are focused on capitalizing on growth opportunities across multiple end markets. This includes the aerospace and defense industry, with opportunities driven by the advancement of communication systems and expanding global air travel. Also, the automotive industry where there are market opportunities resulting from continuing trends in vehicle electrification and ADAS adoption. In the electronics and communications industries there are compelling opportunities resulting from growth in data centers and next-generation smartphones. Industrial markets provide growth opportunities in certain sub-markets, including renewable energy which continues to expand globally.

Our growth strategy is based on addressing trends in these markets and maintaining a strong customer-centric focus. Our sales engineers and technical service employees work closely with our customers to understand their needs and then leverage our development capabilities and applications expertise to provide customized solutions. Our strategy is supported by an expansive product portfolio and a reputation for producing high performance and reliable products. We expect to secure further commercial wins and improve sales as we execute on this strategy.

Our operational excellence efforts are focused on driving ongoing cost improvements and efficiencies to further enhance our profitability while enhancing the agility and customer focus of the organization. These efforts include focusing on improving yields, throughput, procurement capabilities, and manufacturing processes. We have also taken specific cost improvement actions in recent quarters that have and will benefit our performance. These actions include optimizing our manufacturing footprint and reducing manufacturing and corporate employees. We continue to review and re-align our manufacturing and engineering footprint in an effort to maintain a leading competitive position globally and to support our customers' growth initiatives.

We seek to enhance our operational and financial performance by investing in research and development, manufacturing and materials efficiencies, and new product initiatives that respond to the needs of our customers. We strive to evaluate operational and strategic alternatives to improve our business structure and align our business with the changing needs of our customers and evolving industry trends.

If we successfully execute this growth and operational improvement strategy, we see an opportunity, over the next several years, to increase revenues from current levels and further improve profitability. The increase in revenues is largely expected to come from our organic business, with the potential to augment this growth through targeted acquisitions.

**Executive Summary**

The following synopsis and factors should be considered when reviewing our results of operations, financial position and liquidity:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• In the first quarter of 2026 as compared to the first quarter of 2025, our net sales increased approximately 5.2% to $200.5 million, our gross margin increased approximately 230 basis points to 32.2% from 29.9%, and we had an operating margin of 5.3% compared to an operating loss of 0.2%.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• We recognized restructuring charges of $5.7 million in the first quarter of 2026 due to our manufacturing footprint consolidation in our Eschenbach, Germany facility, our executive leadership transition and additional reduction in force actions.

------

**Results of Operations**

The following table sets forth, for the periods indicated, selected operations data expressed as a percentage of net sales:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** |
| | **March 31, 2026** | March 31, 2025 |
| Net sales | **100.0%** | 100.0% |
| Gross margin | **32.2%** | 29.9% |
| Selling, general and administrative expenses | **20.6%** | 23.4% |
| Research and development expenses | **3.4%** | 3.7% |
| Restructuring and impairment charges | **2.9%** | 3.1% |
| Other operating (income) expense, net | **— %** | (0.1)% |
| Operating income (loss) | **5.3%** | (0.2)% |
| Other income (expense), net | **0.1%** | (0.8)% |
| Interest income, net | **0.2%** | 0.2% |
| Income (loss) before income taxes | **5.6%** | (0.8)% |
| Income tax (benefit) expense | **3.4%** | (0.1)% |
| Net income (loss) | **2.2%** | (0.7)% |

---

---

| | | |
|:---|:---|:---|
| ***Net Sales and Gross Margin*** | ***Net Sales and Gross Margin*** | ***Net Sales and Gross Margin*** |
| | **Three Months Ended** | **Three Months Ended** |
| *(Dollars in millions)* | **March 31, 2026** | March 31, 2025 |
| Net sales | $**200.5** | $190.5 |
| Gross margin | $**64.6** | $57.0 |
| Percentage of net sales | **32.2%** | 29.9% |

---

Net sales increased by 5.2%, or $10.0 million, inclusive of a $7.9 million benefit from the appreciation of the euro and Chinese yuan relative to the U.S. dollar. By end market, sales increased in the industrial and electronics and communications markets, partially offset by lower net sales in the automotive market, in the first quarter of 2026 compared to the first quarter of 2025.

Gross margin as a percentage of net sales increased approximately 230 basis points to 32.2% in the first quarter of 2026 compared to 29.9% in the first quarter of 2025. Gross margin in the first quarter of 2026 increased due to higher net sales, favorable mix, and cost savings following our manufacturing footprint consolidation in Belgium.

---

| | | |
|:---|:---|:---|
| ***Selling, General and Administrative Expenses*** | ***Selling, General and Administrative Expenses*** | ***Selling, General and Administrative Expenses*** |
| | **Three Months Ended** | **Three Months Ended** |
| *(Dollars in millions)* | **March 31, 2026** | March 31, 2025 |
| Selling, general and administrative expenses | $**41.2** | $44.5 |
| Percentage of net sales | **20.6%** | 23.4% |

---

SG&A expenses decreased 7.4% in the first quarter of 2026 from the first quarter of 2025, primarily due to a $2.3 million reduction in professional services costs, and a $0.9 million reduction in software costs.

---

| | | |
|:---|:---|:---|
| ***Research and Development Expenses*** | ***Research and Development Expenses*** | ***Research and Development Expenses*** |
| | **Three Months Ended** | **Three Months Ended** |
| *(Dollars in millions)* | **March 31, 2026** | March 31, 2025 |
| Research and development expenses | $**6.7** | $7.1 |
| Percentage of net sales | **3.4%** | 3.7% |

---

R&D expenses decreased 5.6% in the first quarter of 2026 from the first quarter of 2025, primarily due to a reduction in employee compensation and benefits.

------

---

| | | |
|:---|:---|:---|
| ***Restructuring and Impairment Charges*** | ***Restructuring and Impairment Charges*** | ***Restructuring and Impairment Charges*** |
| | **Three Months Ended** | **Three Months Ended** |
| *(Dollars in millions)* | **March 31, 2026** | March 31, 2025 |
| Restructuring and impairment charges | $**5.9** | $5.9 |

---

We incurred restructuring and impairment charges of $5.9 million in the three months ended March 31, 2026, due to our footprint consolidation actions in our Eschenbach, Germany facility, the executive leadership transition an additional reduction in force, and the impairment of our Mexico facility lease. For additional information, refer to "Note 13 – Supplemental Financial Information" to the condensed consolidated financial statements in Part I, Item 1, of this Form 10-Q.

---

| | | |
|:---|:---|:---|
| ***Other Income (Expense), Net*** | ***Other Income (Expense), Net*** | ***Other Income (Expense), Net*** |
| | **Three Months Ended** | **Three Months Ended** |
| *(Dollars in millions)* | **March 31, 2026** | March 31, 2025 |
| Other income (expense), net | $**0.3** | $(1.6) |

---

Other income (expense), net was income of $0.3 million in the first quarter of 2026 compared to expense of $1.6 million in the first quarter of 2025. The increase was primarily due to $2.6 million of favorable year-over-year changes in impacts from foreign currency transactions, partially offset by $1.0 million in unfavorable performance on foreign exchange and copper derivative contracts.

---

| | | |
|:---|:---|:---|
| ***Interest Income, Net*** | ***Interest Income, Net*** | ***Interest Income, Net*** |
| | **Three Months Ended** | **Three Months Ended** |
| *(Dollars in millions)* | **March 31, 2026** | March 31, 2025 |
| Interest income, net | $**0.3** | $0.3 |

---

Interest income, net, was flat year-over-year.

---

| | | |
|:---|:---|:---|
| ***Income Taxes*** | ***Income Taxes*** | ***Income Taxes*** |
| | **Three Months Ended** | **Three Months Ended** |
| *(Dollars in millions)* | **March 31, 2026** | March 31, 2025 |
| Income tax (benefit) expense | $**6.8** | $(0.2) |
| Effective tax rate | **60.2%** | 12.5% |

---

Compared to the 21% U.S. statutory federal income tax rate, we had a tax rate of 60.2% in the first quarter of 2026. During the quarter, our effective tax rate was unfavorably impacted by an increase in the valuation allowance attributable to loss jurisdictions in which no tax benefit is anticipated to be realized.

We had a tax rate of 12.5% in the first quarter of 2025 when we incurred a loss before income taxes of $1.6 million, which, when taxed at the 21% U.S. statutory federal income tax rate, resulted in an immaterial income tax benefit, partially offset by insignificant tax adjustments that caused the effective tax rate to differ from the statutory rate.

**Operating Segment Net Sales and Gross Margin**

***Advanced Electronics Solutions***

---

| | | |
|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** |
| *(Dollars in millions)* | **March 31, 2026** | March 31, 2025 |
| Net sales | $**107.7** | $104.2 |
| Gross margin | $**31.4** | $29.1 |
| Percentage of net sales | **29.2%** | 27.9% |

---

AES net sales increased by 3.4%, or $3.5 million, inclusive of a $5.3 million benefit from the appreciation of the euro and Chinese yuan relative to the U.S. dollar. Inclusive of the foreign currency benefits, net sales by end market increased for electronics and communications, and industrial, while net sales in the aerospace and defense market were lower, in the first quarter of 2026 compared to the first quarter of 2025.

------

Our AES operating and reportable segment gross margin as a percentage of net sales in the first quarter of 2026 was 29.2% as compared to 27.9% in the first quarter of 2025. Gross margin improved primarily due to cost savings following our manufacturing footprint consolidation in Belgium, partially offset by lower utilization from a new production line.

***Elastomeric Material Solutions***

---

| | | |
|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** |
| *(Dollars in millions)* | **March 31, 2026** | March 31, 2025 |
| Net sales | $**88.4** | $82.6 |
| Gross margin | $**31.3** | $26.7 |
| Percentage of net sales | **35.4%** | 32.3% |

---

EMS net sales increased by 7.0%, or $5.8 million, including $2.5 million of favorable impact from the appreciation of the euro and Chinese yuan relative to the U.S. dollar. By end market, sales increased in the industrial, electronics and communications, and aerospace and defense markets, partially offset by lower sales in the automotive market, in the first quarter of 2026 compared to the first quarter of 2025.

Our EMS operating and reportable segment gross margin as a percentage of net sales in the first quarter of 2026 was 35.4% as compared to 32.3% in the first quarter of 2025. Gross margin improved primarily due to increased sales volume and related utilization benefits and favorable mix.

***Other***

---

| | | |
|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** |
| *(Dollars in millions)* | **March 31, 2026** | March 31, 2025 |
| Net sales | $**4.4** | $3.7 |
| Gross margin | $**1.9** | $1.2 |
| Percentage of net sales | **43.2%** | 32.4% |

---

**Liquidity, Capital Resources and Financial Position**

We believe that our existing sources of liquidity and cash flows that we expect to generate from our operations, together with our available credit facilities, will be sufficient to fund our operations, currently planned capital expenditures and R&D efforts, for at least the next 12 months. We regularly review and evaluate the adequacy of our cash flows, borrowing facilities and banking relationships in an effort to ensure that we have the appropriate access to cash to fund both our near-term operating needs and our long-term strategic initiatives.

The following table illustrates the location of our cash and cash equivalents by our three major geographic areas:

---

| | | |
|:---|:---|:---|
| *(Dollars in millions)* | **March 31, 2026** | December 31, 2025 |
| U.S. | $**109.3** | $100.1 |
| Europe | **44.2** | 40.7 |
| Asia | **42.3** | 56.2 |
| ***Total cash and cash equivalents*** | $**195.8** | $197.0 |

---

Approximately $86.5 million of our cash and cash equivalents were held by non-U.S. subsidiaries as of March 31, 2026. We did not make any changes in the three months ended March 31, 2026 to our position on the permanent reinvestment of our earnings from foreign operations. With the exception of certain of our Chinese subsidiaries, where a substantial portion of our cash and cash equivalents located in Asia are held, we continue to assert that historical foreign earnings are indefinitely reinvested.

---

| | | |
|:---|:---|:---|
| *(Dollars in millions)* | **March 31, 2026** | December 31, 2025 |
| *Key Financial Position Accounts:* |  |  |
| &nbsp;&nbsp;&nbsp;Cash and cash equivalents | $**195.8** | $197.0 |
| &nbsp;&nbsp;&nbsp;Accounts receivable, net | $**142.1** | $130.6 |
| &nbsp;&nbsp;&nbsp;Inventories, net | $**127.5** | $125.0 |

---

------

Changes in key financial position accounts and other significant changes in our statements of financial position from December 31, 2025 to March 31, 2026 were as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Cash and cash equivalents were $195.8 million as compared to $197.0 million as of December 31, 2025, a decrease of $1.2 million, or 0.6%. This decrease was primarily due to cash used in investing and financing activities, partially offset by cash provided by operations and favorable impacts of exchange rates on cash.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Accounts receivable, net increased 8.8% to $142.1 million as of March 31, 2026 from $130.6 million as of December 31, 2025. The increase was primarily due to higher net sales in the last month of the first quarter of 2026 compared to the last month of the fourth quarter of 2025.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Inventories were $127.5 million as of March 31, 2026, compared to $125.0 million as of December 31, 2025. The change was due to higher levels of raw materials and work-in-process inventory, offset by lower levels of finished goods.

---

| | | |
|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** |
| *(Dollars in millions)* | **March 31, 2026** | March 31, 2025 |
| *Key Cash Flow Measures:* |  |  |
| &nbsp;&nbsp;&nbsp;Net cash provided by operating activities | $**5.8** | $11.7 |
| &nbsp;&nbsp;&nbsp;Net cash provided by (used in) investing activities | $**(4.5)** | $3.9 |
| &nbsp;&nbsp;&nbsp;Net cash used in financing activities | $**(1.6)** | $(1.6) |

---

In 2026, we expect capital spending to be in the range of approximately $30.0 million to $40.0 million. We plan to fund our capital spending in 2026 with cash from operations and cash on-hand.

***Restrictions on Payment of Dividends***

The Fifth Amended Credit Agreement generally permits us to pay cash dividends to our shareholders, provided that (i) no default or event of default has occurred and is continuing or would result from the dividend payment and (ii) our total net leverage ratio does not exceed 2.75 to 1.00. If our total net leverage ratio exceeds 2.75 to 1.00, we may nonetheless make up to $20.0 million in restricted payments, including cash dividends, during the fiscal year, provided that no default or event of default has occurred and is continuing or would result from the payments. Our total net leverage ratio did not exceed 2.75 to 1.00 as of March 31, 2026.

**Contingencies**

During the first quarter of 2026, we did not become aware of any material developments related to environmental matters disclosed in our Annual Report, our asbestos litigation or other material contingencies previously disclosed or incur any material costs or capital expenditures related to such matters. Refer to "Note 9 – Commitments and Contingencies" to the condensed consolidated financial statements in Part I, Item 1 of this Form 10-Q for further discussion of these contingencies.

**Critical Accounting Policies and Estimates**

There have been no material changes in our critical accounting policies and estimates from those disclosed in our Annual Report.

**Item 3.&nbsp;&nbsp;&nbsp;&nbsp;Quantitative and Qualitative Disclosures About Market Risk**

There have been no material changes in our exposure to market risk during the first quarter of 2026. For discussion of our exposure to market risk, refer to "Item 7A. *Quantitative and Qualitative Disclosures About Market Risk*" contained in our Annual Report.

**Item 4.&nbsp;&nbsp;&nbsp;&nbsp;Controls and Procedures**

***Evaluation of Disclosure Controls and Procedures***

We conducted, with the participation of our Principal Executive Officer and our Principal Financial Officer, an evaluation of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d- 15(e) under the Exchange Act, as of March 31, 2026. Our disclosure controls and procedures are designed (i) to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms and (ii) to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is accumulated and communicated to our management, including our Principal Executive Officer and our Principal Financial Officer, as appropriate to allow timely decisions regarding required disclosure. Based on their evaluation, our Principal Executive Officer and our Principal Financial Officer concluded that our disclosure controls and procedures were effective as of March 31, 2026.

------

***Changes in Internal Control over Financial Reporting***

We are in the process of a multi-year implementation of a new global ERP system, which will replace our existing operating and financial systems. The implementation is expected to occur in phases over the next several years. The portion of the transition to the new ERP system that we have completed to date did not result in significant changes in our internal control over financial reporting. However, as the next phases of the updated processes are rolled out in connection with the ERP implementation, we will give appropriate consideration to whether these process changes necessitate changes in the design of and the testing for effectiveness of internal controls over financial reporting.

There were no changes in the Company's internal control over financial reporting during the first quarter of fiscal year ending December 31, 2026, that have materially affected or are reasonably likely to materially affect the Company's internal control over financial reporting, as defined in Rule 13a-15(f) and 15d-15(f) under the Exchange Act.

**Part II - Other Information**

**Item 1.&nbsp;&nbsp;&nbsp;&nbsp;Legal Proceedings**

Refer to the discussion of certain environmental, asbestos and other litigation matters in "Note 9 – Commitments and Contingencies" to the condensed consolidated financial statements in Part I, Item 1 of this Form 10-Q.

**Item 1A. Risk Factors**

In addition to the other information set forth in this Form 10-Q, you should carefully consider factors discussed in Part I, Item 1A "Risk Factors" of our Annual Report on Form 10-K for the year ended December 31, 2025 and the Company's other filings with the SEC, which are available at www.sec.gov and on the Company's website at www.rogerscorp.com.

**Item 5. Other Information**

During the three months ended March 31, 2026, none of our directors or officers adopted or terminated a "Rule 10b5-1 trading arrangement" or a "non-Rule 10b5-1 trading arrangement", as each term is defined in Item 408 of Regulation S-K.

**Item 6.&nbsp;&nbsp;&nbsp;&nbsp;Exhibits**

---

| | |
|:---|:---|
| List of Exhibits: | List of Exhibits: |
| 31.1 | <u>[Certification of Principal Executive Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, filed herewith.](rog-20260331x10ex311.htm)</u> |
| 31.2 | <u>[Certification of Senior Vice President, Chief Financial Officer and Treasurer (Principal Financial Officer) pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, filed herewith.](rog-20260331x10ex312.htm)</u> |
| 32 | <u>[Certification of Principal Executive Officer and Senior Vice President and Chief Financial Officer and Treasurer (Principal Financial Officer) pursuant to Rule 13a-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, furnished herewith.](rog-20260331x10ex32.htm)</u> |
| 101 | The following materials from Rogers Corporation's Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2026 formatted in iXBRL (Inline Extensible Business Reporting Language): (i) Condensed Consolidated Statements of Operations for the three months ended March 31, 2026 and March 31, 2025, (ii) Condensed Consolidated Statements of Comprehensive Income (Loss) for the three months ended March 31, 2026 and March 31, 2025, (iii) Condensed Consolidated Statements of Financial Position as of March 31, 2026 and December 31, 2025, (iv) Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2026 and March 31, 2025, (v) Condensed Consolidated Statements of Shareholders' Equity for the three months ended March 31, 2026 and March 31, 2025, (vi) Notes to Condensed Consolidated Financial Statements and (vii) Cover Page. |
| 104 | The cover page from Rogers Corporation's Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2026, formatted in iXBRL and contained in Exhibit 101. |

---

------

**Signatures**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

ROGERS CORPORATION(Registrant)

---

| |
|:---|
| By: /s/ Laura Russell |
| Laura Russell |
| *Senior Vice President, Chief Financial Officer and Treasurer* |
| *Principal Financial Officer* |
| Dated: April 28, 2026 |

---

## Exhibit 31.1

**Exhibit 31.1**

**CERTIFICATIONS**

I, Ali El-Haj, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Rogers Corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c.Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d.Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| |
|:---|
| Dated: April 28, 2026 |
| By: /s/ Ali El-Haj |
| Ali Eli-Haj |
| *Interim President and Chief Executive Officer<br>Principal Executive Officer* |

---

## Exhibit 31.2

**Exhibit 31.2**

**CERTIFICATIONS**

I, Laura Russell, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Rogers Corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c.Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d.Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| |
|:---|
| Dated: April 28, 2026 |
| By: /s/ Laura Russell |
| Laura Russell |
| *Senior Vice President, Chief Financial Officer and Treasurer<br>Principal Financial Officer* |

---

## Ex-32

**Exhibit 32** 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, each of the undersigned officers of Rogers Corporation, a Massachusetts corporation (the "Corporation"), does hereby certify that:

The Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2026 (the "Form 10-Q") of the Corporation fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Corporation.

---

| |
|:---|
| By: /s/ Ali El-Haj |
| Ali Eli-Haj |
| *Interim President and Chief Executive Officer<br>Principal Executive Officer* |
| April 28, 2026 |

---

---

| |
|:---|
| By: /s/ Laura Russell |
| Laura Russell |
| *Senior Vice President, Chief Financial Officer and Treasurer*<br>*Principal Financial Officer* |
| April 28, 2026 |

---

<br>